Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pancrelipase is a combination of porcine-derived digestive enzymes, including lipase, amylase, and protease, used as pancreatic enzyme replacement therapy (PERT). It is indicated for the treatment of pancreatic exocrine insufficiency (PEI) associated with conditions such as cystic fibrosis, chronic pancreatitis, and pancreatic surgery. Sunnybrook Health Sciences Centre is conducting the PERQ-UP pilot randomized controlled trial to evaluate the feasibility and efficacy of initiating PERT immediately following pancreaticoduodenectomy (Whipple procedure) to improve patient quality of life and nutritional outcomes, compared to the standard of care where PERT is only started upon the development of clinical symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancrelipase (Sunnybrook Health Sciences Centre).